Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial in 706 adults with overweight or obesity, once-weekly doses reduced body weight by 6.0% to 10.8% against 3.0% on placebo, with more nausea.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial in 706 adults with overweight or obesity, once-weekly doses reduced body weight by 6.0% to 10.8% against 3.0% on placebo, with more nausea. · pmid:34798060
In a 68-week phase 3a trial in 3,417 adults, cagrilintide combined with semaglutide reduced body weight by 20.4% against 3.0% on placebo. · pmid:40544433
Proportion of the 2 claims about Cagrilintide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cagrilintide yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. · pmid 40544433 · 2025
Observational evidence· resolved human data at the emerging tier: thin, or contested
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. · pmid 34798060 · 2021
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.